Form 4: Humacyte Director Acquires Stock Options
SEC Form 4 Filing
Brady W. Dougan, a director of Humacyte, Inc., acquired stock options indirectly through a spouse.
Summary
- On January 21, 2025, Brady W. Dougan, a director of Humacyte, Inc., acquired 1,130,311 stock options with an exercise price of $4.56.
- The options are exercisable beginning January 21, 2026, with 25% vesting initially, followed by 1/48th vesting monthly until January 21, 2029.
- The options expire on January 21, 2035.
- The acquisition was made indirectly through a spouse.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock option acquisition.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director can signal confidence in the company's future prospects to shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of transaction: acquisition of stock options |
| 01/21/2026 | First 25% of the option becomes exercisable |
| 01/21/2029 | End of monthly vesting period for the option |
| 01/21/2035 | Expiration date of the stock options |
| 01/23/2025 | Date of signature |
Keywords
stock options, Form 4, Humacyte, director, acquisition, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.